entertainment -WSS

entertainment

author：comprehensive 2025-09-28 13:23:32 - browse：1268

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How to save health care price transparency rules

focus

explore

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout Newsletter: XBI biotech index, Akero Therapeutics

Traditional Chinese medicine benefits explored in new JAMA study

Maker of FluMist seeks to allow at

Readout Newsletter: XBI biotech index, Akero Therapeutics

focus

entertainment

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

How many hemophilia patients actually want gene therapy?

Apple is now the first public company to be valued at $3 trillion

Emergency medicine has repudiated 'excited delirium.' Now what?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

The high cost of giving birth even with insurance

The FDA weighs the risks of candy

What does generative AI mean for health care? We asked experts

Pushing for an NIH office for post

Wikipedia

Maker of FluMist seeks to allow at

As AI in medicine takes off, can 'human in the loop' prevent harm?

Traditional Chinese medicine benefits explored in new JAMA study

FDA advisers back CAR

FDA advisers back CAR

RaDonda Vaught links Vanderbilt hospital issues to patient death

Wikipedia

focus

explore

Wikipedia